The problem developing new antibiotics is not the science it is economic and regulatory. Let&#x27;s say you are crazy enough to pay the enormous cost of bring a new antibiotic through the regulatory process, your new antibiotic doesn&#x27;t get used by doctors. They put the new antibiotic on the shelf to be used in emergencies when all the other antibiotics haven&#x27;t worked. Your sales are then near zero. This is why all the major pharmaceutical companies have shut down their antibiotic divisions.<p>What we need to work towards is a large cash payment on approval of each drug or a guaranteed minimium annual payment. Once we have this we will start to get the new antibiotics we need.